Literature DB >> 30248523

IL-6: a cytokine at the crossroads of autoimmunity.

Britta E Jones1, Megan D Maerz1, Jane H Buckner2.   

Abstract

IL-6 is implicated in the development and progression of autoimmune diseases in part by influencing CD4 T cell lineage and regulation. Elevated IL-6 levels drive inflammation in a wide range of autoimmune diseases, some of which are also characterized by enhanced T cell responses to IL-6. Notably, the impact of IL-6 on inflammation is contextual in nature and dependent on the cell type, cytokine milieu and tissue. Targeting the IL-6/IL-6R axis in humans has been shown to successfully ameliorate a subset of autoimmune conditions. In this review, we discuss recent studies investigating how IL-6 regulates the CD4 T cell response in the context of autoimmune disease and highlight how blocking different aspects of the IL-6 pathway is advantageous in the treatment of disease.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30248523      PMCID： PMC6286200          DOI： 10.1016/j.coi.2018.09.002

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  60 in total

1.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

2.  Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

Authors:  Dinesh Khanna; Christopher P Denton; Angelika Jahreis; Jacob M van Laar; Tracy M Frech; Marina E Anderson; Murray Baron; Lorinda Chung; Gerhard Fierlbeck; Santhanam Lakshminarayanan; Yannick Allanore; Janet E Pope; Gabriela Riemekasten; Virginia Steen; Ulf Müller-Ladner; Robert Lafyatis; Giuseppina Stifano; Helen Spotswood; Haiyin Chen-Harris; Sebastian Dziadek; Alyssa Morimoto; Thierry Sornasse; Jeffrey Siegel; Daniel E Furst
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

3.  The contribution of the functional IL6R polymorphism rs2228145, eQTLs and other genome-wide SNPs to the heritability of plasma sIL-6R levels.

Authors:  Jenny van Dongen; Rick Jansen; Dirk Smit; Jouke-Jan Hottenga; Hamdi Mbarek; Gonneke Willemsen; Cornelis Kluft; Brenda W J Penninx; Manuel A Ferreira; Dorret I Boomsma; Eco J C de Geus
Journal:  Behav Genet       Date:  2014-05-03       Impact factor: 2.805

4.  A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

Authors:  Robert Z Orlowski; Liana Gercheva; Cathy Williams; Heather Sutherland; Tadeusz Robak; Tamás Masszi; Vesselina Goranova-Marinova; Meletios A Dimopoulos; James D Cavenagh; Ivan Špička; Angelo Maiolino; Alexander Suvorov; Joan Bladé; Olga Samoylova; Thomas A Puchalski; Manjula Reddy; Rajesh Bandekar; Helgi van de Velde; Hong Xie; Jean-Franςois Rossi
Journal:  Am J Hematol       Date:  2015-01       Impact factor: 10.047

5.  IL-6 detection in multiple sclerosis brain.

Authors:  D Maimone; G C Guazzi; P Annunziata
Journal:  J Neurol Sci       Date:  1997-02-27       Impact factor: 3.181

6.  Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.

Authors:  Milène Kennedy Crispin; Justin M Ko; Brittany G Craiglow; Shufeng Li; Gautam Shankar; Jennifer R Urban; James C Chen; Jane E Cerise; Ali Jabbari; Mårten Cg Winge; M Peter Marinkovich; Angela M Christiano; Anthony E Oro; Brett A King
Journal:  JCI Insight       Date:  2016-09-22

7.  Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.

Authors:  M Narazaki; K Yasukawa; T Saito; Y Ohsugi; H Fukui; Y Koishihara; G D Yancopoulos; T Taga; T Kishimoto
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

8.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

Authors:  Marc Veldhoen; Richard J Hocking; Christopher J Atkins; Richard M Locksley; Brigitta Stockinger
Journal:  Immunity       Date:  2006-02       Impact factor: 31.745

9.  Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases.

Authors:  Ricardo C Ferreira; Daniel F Freitag; Antony J Cutler; Joanna M M Howson; Daniel B Rainbow; Deborah J Smyth; Stephen Kaptoge; Pamela Clarke; Charlotte Boreham; Richard M Coulson; Marcin L Pekalski; Wei-Min Chen; Suna Onengut-Gumuscu; Stephen S Rich; Adam S Butterworth; Anders Malarstig; John Danesh; John A Todd
Journal:  PLoS Genet       Date:  2013-04-04       Impact factor: 5.917

10.  B cell-derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity.

Authors:  Tanvi Arkatkar; Samuel W Du; Holly M Jacobs; Elizabeth M Dam; Baidong Hou; Jane H Buckner; David J Rawlings; Shaun W Jackson
Journal:  J Exp Med       Date:  2017-09-12       Impact factor: 14.307
View more
  33 in total

Review 1.  The Immunobiology of the Interleukin-12 Family: Room for Discovery.

Authors:  Elia D Tait Wojno; Christopher A Hunter; Jason S Stumhofer
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

Review 2.  Roles of Interleukin-6-mediated immunometabolic reprogramming in COVID-19 and other viral infection-associated diseases.

Authors:  Ying-Shuang Li; Hua-Cheng Ren; Jian-Hua Cao
Journal:  Int Immunopharmacol       Date:  2022-06-28       Impact factor: 5.714

3.  Study the Mechanism of Gualou Niubang Decoction in Treating Plasma Cell Mastitis Based on Network Pharmacology and Molecular Docking.

Authors:  Zhaojing Wu; Qing Yang; Hongbo Ma
Journal:  Biomed Res Int       Date:  2022-06-15       Impact factor: 3.246

Review 4.  Salivary gland function, development, and regeneration.

Authors:  Alejandro M Chibly; Marit H Aure; Vaishali N Patel; Matthew P Hoffman
Journal:  Physiol Rev       Date:  2022-03-28       Impact factor: 46.500

5.  Type II but Not Type I IFN Signaling Is Indispensable for TLR7-Promoted Development of Autoreactive B Cells and Systemic Autoimmunity.

Authors:  Sathi Babu Chodisetti; Adam J Fike; Phillip P Domeier; Harinder Singh; Nicholas M Choi; Chelsea Corradetti; Yuka Imamura Kawasawa; Timothy K Cooper; Roberto Caricchio; Ziaur S M Rahman
Journal:  J Immunol       Date:  2020-01-03       Impact factor: 5.422

6.  Acid Sphingomyelinase and Acid β-Glucosidase 1 Exert Opposite Effects on Interleukin-1β-Induced Interleukin 6 Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes.

Authors:  Mengmeng Zhao; Maowei Yang; Xu Li; Linxin Hou; Xudong Liu; Weiguo Xiao
Journal:  Inflammation       Date:  2021-03-04       Impact factor: 4.092

7.  Novel Approaches for Immunosuppression in Graves' Hyperthyroidism and Associated Orbitopathy.

Authors:  Alan Chun Hong Lee; George J Kahaly
Journal:  Eur Thyroid J       Date:  2020-08-10

8.  IL-6 enhances CD4 cell motility by sustaining mitochondrial Ca2+ through the noncanonical STAT3 pathway.

Authors:  Felipe Valença-Pereira; Qian Fang; Isabelle J Marié; Emily L Giddings; Karen A Fortner; Rui Yang; Alejandro V Villarino; Yina H Huang; David A Frank; Haitao Wen; David E Levy; Mercedes Rincon
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-14       Impact factor: 12.779

9.  Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine.

Authors:  Robert O Dillman; Gabriel I Nistor; Aleksandra J Poole
Journal:  Hum Vaccin Immunother       Date:  2019-11-15       Impact factor: 3.452

Review 10.  Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption.

Authors:  Tuğçe Nur Yiğenoğlu; Turgay Ulas; Mehmet Sinan Dal; Serdal Korkmaz; Mehmet Ali Erkurt; Fevzi Altuntaş
Journal:  Transfus Apher Sci       Date:  2020-06-25       Impact factor: 2.596
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.